Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...
M. Szarek, D. L. Bhatt, M. Miller et al.· European Heart Journal· 0 citations
Among adults with T2D and overweight/obesity, IL-6 identified residual inflammatory risk of incident HF, particularly among adults with no CVD history, particularly among adults with no CVD history.
Kershaw V. Patel, Leonard Chiu, Katelyn R. Garcia et al.· JACC. Heart failure· 1 citation
Among hypertensive adults, the coexistence of prediabetes and malignant LVH identifies a subgroup at substantially elevated HF risk, and integrating glycemic status, ECG findings, and cardiac biomarkers may enhance HF risk stratification and inform preventive strategies.
Arnaud D. Kaze, Stephen P. Juraschek, Jordana B. Cohen et al.· JACC: Advances· 0 citations
Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.
M. Szarek, Deepak L. Bhatt, Michael Miller et al.· Journal of Clinical Lipidolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.